N@N

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

^{Published on 2012-11-09 04:00:55 - Market Wire}
 

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

BOTHELL, WA and VANCOUVER, BC, Nov. 9, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: [ OGXI ]) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 14, 2012 at 10:00 a.m. ET at the Pierre Hotel in New York City.

Live audio webcasts can be accessed through the Investor Relations page of the OncoGenex website at [ www.oncogenex.com ]. Webcast replays will be archived for 60 days.

About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at [ www.OncoGenex.com ]

SOURCE OncoGenex Pharmaceuticals, Inc.